EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted Therapy in the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)

Elena Pontarini iD, Elisabetta Sciacca iD, Farzana Chowdhury, Sofia Grigoriadou, Felice Rivellese iD, William J Murray-Brown, Davide Lucchesi iD, Liliante Fossati-Jimack iD, Alessandra Nerviani, Edyta Jaworska iD, Giulia Maria Ghirardi, Chiara Giacomassi und 20 weitere

Arthritis & Rheumatology · 2024-05 · 76 (5) · 763-776

DOI: 10.1002/art.42772 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 15.02.2024. Verfasst von Elena Pontarini und 31 weiteren Autor:innen. Beteiligte Einrichtung: Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Rituximab, Biomarkers, B-Lymphocytes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Versus Arthritis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to identify peripheral and salivary gland (SG) biomarkers of response/resistance to B cell depletion based on the novel concise Composite of Relevant Endpoints for Sjögren Syndrome (cCRESS) and candidate Sjögren Tool for Assessing Response (STAR) composite endpoints.

Methods

Longitudinal analysis of peripheral blood and SG biopsies was performed pre‐ and post‐treatment from the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS) combining flow cytometry immunophenotyping, serum cytokines, and SG bulk RNA sequencing.

Results

Rituximab treatment prevented the worsening of SG inflammation observed in the placebo arm, by inhibiting the accumulation of class‐switched memory B cells within the SG. Furthermore, rituximab significantly down‐regulated genes involved in immune‐cell recruitment, lymphoid organization alongside antigen presentation, and T cell co‐stimulatory pathways. In the peripheral compartment, rituximab down‐regulated immunoglobulins and auto‐antibodies together with pro‐inflammatory cytokines and chemokines. Interestingly, patients classified as responders according to STAR displayed significantly higher baseline levels of C‐X‐C motif chemokine ligand‐13 (CXCL13), interleukin (IL)‐22, IL‐17A, IL‐17F, and tumor necrosis factor‐α (TNF‐α), whereas a longitudinal analysis of serum T cell–related cytokines showed a selective reduction in both STAR and cCRESS responder patients. Conversely, cCRESS response was better associated with biomarkers of SG immunopathology, with cCRESS‐responders showing a significant decrease in SG B cell infiltration and reduced expression of transcriptional gene modules related to T cell costimulation, complement activation, and Fcγ‐receptor engagement. Finally, cCRESS and STAR response were associated with a significant improvement in SG exocrine function linked to transcriptional evidence of SG epithelial and metabolic restoration.

Conclusion

Rituximab modulates both peripheral and SG inflammation, preventing the deterioration of exocrine function with functional and metabolic restoration of the glandular epithelium. Response assessed by newly developed cCRESS and STAR criteria was associated with differential modulation of peripheral and SG biomarkers, emerging as novel tools for patient stratification. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeRituximabBiomarkersB-LymphocytesSalivary GlandsHumansChemokine CXCL13CytokinesFemaleInterleukin-17Middle AgedLongitudinal StudiesTreatment Outcome

Substanzen

RituximabBiomarkersChemokine CXCL13CytokinesCXCL13 protein, humanInterleukin-17

Autor:innen und Institutionen

  • Queen Mary University of London, London, UK.
  • Queen Mary University of London and Bart's Health NHS Trust, London, UK.
  • University of Leeds, Leeds, UK.
  • Newcastle University and NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne, UK.
  • Bart's Health NHS Trust, London, UK.
  • Université' Paris-Saclay, and AP-HP, Hôpital Bicêtre, Le Kremlin, Bicêtre, France.

ORCID-Profile: Elena Pontarini, Elisabetta Sciacca, Felice Rivellese, Davide Lucchesi, Liliante Fossati-Jimack, Edyta Jaworska, Paul Emery, Wan Fai Ng, Colin Everett, Anwar Tappuni, Giulia Cavallaro, Alfredo Pulvirenti, Gwenny M Verstappen, Liseth de Wolff, Miles J Lewis, Constantino Pitzalis, Michele Bombardieri

Förderung

  • Wellcome Trust
  • Medical Research Council
  • Versus Arthritis
  • William Harvey Research Foundation
  • NIHR Barts BRC
  • European Federation of Pharmaceutical Industries and Associations
  • NIHR Birmingham Biomedical Research Centre

Zitieren

APA

Pontarini, E., Sciacca, E., Chowdhury, F., Grigoriadou, S., Rivellese, F., Murray-Brown, W. J., Lucchesi, D., Fossati-Jimack, L., Nerviani, A., Jaworska, E., Ghirardi, G. M., Giacomassi, C., Emery, P., Ng, W. F., Sutcliffe, N., Everett, C., Fernandez, C., Tappuni, A., Seror, R., …, & Trial for Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome Study Research Group (2024). Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted Therapy in the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS). Arthritis & Rheumatology, 76(5), 763-776. https://doi.org/10.1002/art.42772

Vancouver

Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, et al. Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted Therapy in the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS). Arthritis & Rheumatology. 2024;76(5):763-776. doi:10.1002/art.42772

BibTeX
@article{Pontarini2024,
  author = {Pontarini, Elena and Sciacca, Elisabetta and Chowdhury, Farzana and Grigoriadou, Sofia and Rivellese, Felice and Murray-Brown, William J and Lucchesi, Davide and Fossati-Jimack, Liliante and Nerviani, Alessandra and Jaworska, Edyta and Ghirardi, Giulia Maria and Giacomassi, Chiara and Emery, Paul and Ng, Wan Fai and Sutcliffe, Nurhan and Everett, Colin and Fernandez, Catherine and Tappuni, Anwar and Seror, Raphael and Mariette, Xavier and Porcher, Raphael and Cavallaro, Giulia and Pulvirenti, Alfredo and Verstappen, Gwenny M and de Wolff, Liseth and Arends, Suzanne and Bootsma, Hendrika and Lewis, Miles J and Pitzalis, Constantino and Bowman, Simon J and Bombardieri, Michele and Trial for Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome Study Research Group, Trial for Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome Study Research Group},
  title = {Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted Therapy in the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  volume = {76},
  number = {5},
  pages = {763--776},
  doi = {10.1002/art.42772}
}
Kostenlos starten →